CDK1 and cancer: Because MiDAS is elevated in cells challenged with RS and is especially prevalent in aneuploid cancer cells with oncogene activation, inhibition of CDK1 may provide a therapeutic intervention in cancers with elevated TDP1 expression, which is known to cause chromosomal instability (Duffy et al, 2016).